178 related articles for article (PubMed ID: 26381302)
1. Molecular biomarkers added to image-enhanced endoscopic imaging: will they further improve diagnostic accuracy?
Krishnamoorthi R; Iyer PG
Best Pract Res Clin Gastroenterol; 2015 Aug; 29(4):561-73. PubMed ID: 26381302
[TBL] [Abstract][Full Text] [Related]
2. Screening and surveillance for Barrett's esophagus: current issues and future directions.
Choi SE; Hur C
Curr Opin Gastroenterol; 2012 Jul; 28(4):377-81. PubMed ID: 22508325
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
[TBL] [Abstract][Full Text] [Related]
4. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
5. Surveillance in Barrett's esophagus: a failed premise.
Inadomi JM
Keio J Med; 2009 Mar; 58(1):12-8. PubMed ID: 19398879
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
7. Novel Screening Tests for Barrett's Esophagus.
Codipilly DC; Iyer PG
Curr Gastroenterol Rep; 2019 Jul; 21(9):42. PubMed ID: 31346777
[TBL] [Abstract][Full Text] [Related]
8. Barrett's esophagus and Barrett's-related dysplasia.
Goldblum JR
Mod Pathol; 2003 Apr; 16(4):316-24. PubMed ID: 12692197
[TBL] [Abstract][Full Text] [Related]
9. Management of low-grade dysplasia in Barrett's esophagus.
Wani S
Curr Opin Gastroenterol; 2012 Jul; 28(4):370-6. PubMed ID: 22508323
[TBL] [Abstract][Full Text] [Related]
10. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
11. Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus.
Lovat LB; Johnson K; Mackenzie GD; Clark BR; Novelli MR; Davies S; O'Donovan M; Selvasekar C; Thorpe SM; Pickard D; Fitzgerald R; Fearn T; Bigio I; Bown SG
Gut; 2006 Aug; 55(8):1078-83. PubMed ID: 16469795
[TBL] [Abstract][Full Text] [Related]
12. Beyond Dysplasia Grade: The Role of Biomarkers in Stratifying Risk.
Dunbar KB; Souza RF
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):447-459. PubMed ID: 28577766
[TBL] [Abstract][Full Text] [Related]
13. Computer-aided diagnosis of dysplasia in Barrett's esophagus using endoscopic optical coherence tomography.
Qi X; Sivak MV; Isenberg G; Willis JE; Rollins AM
J Biomed Opt; 2006; 11(4):044010. PubMed ID: 16965167
[TBL] [Abstract][Full Text] [Related]
14. Management of cancer risk in Barrett's esophagus.
Tan A; Macrae F
J Gastroenterol Hepatol; 2011 Oct; 26(10):1485-92. PubMed ID: 21592226
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
Darlavoix T; Seelentag W; Yan P; Bachmann A; Bosman FT
Virchows Arch; 2009 Jun; 454(6):629-37. PubMed ID: 19396460
[TBL] [Abstract][Full Text] [Related]
16. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.
Lu D; Vohra P; Chu PG; Woda B; Rock KL; Jiang Z
Am J Surg Pathol; 2009 Apr; 33(4):521-5. PubMed ID: 19047899
[TBL] [Abstract][Full Text] [Related]
17. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.
Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C
Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102
[TBL] [Abstract][Full Text] [Related]
18. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
[TBL] [Abstract][Full Text] [Related]
19. Evidence for enhanced telomerase activity in Barrett's esophagus with dysplasia and adenocarcinoma.
Merchant NB; Dutta SK; Girotra M; Arora M; Meltzer SJ
Asian Pac J Cancer Prev; 2013; 14(2):679-83. PubMed ID: 23621218
[TBL] [Abstract][Full Text] [Related]
20. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
